Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) SVP Sells $367,710.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) SVP Mark Jeffrey Delong sold 7,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $52.53, for a total transaction of $367,710.00. Following the sale, the senior vice president now owns 28,481 shares in the company, valued at $1,496,106.93. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of APLS traded down $2.63 during midday trading on Friday, hitting $48.24. 1,069,056 shares of the company traded hands, compared to its average volume of 1,100,270. The stock has a 50-day moving average of $48.56 and a 200-day moving average of $43.29. Apellis Pharmaceuticals, Inc. has a one year low of $27.50 and a one year high of $73.00. The firm has a market cap of $5.12 billion, a P/E ratio of -5.50 and a beta of 1.61. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.25 and a quick ratio of 6.13.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last issued its earnings results on Monday, February 28th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.54) by ($0.07). During the same period last year, the firm earned $0.93 earnings per share. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -5.26 EPS for the current fiscal year.

APLS has been the topic of several recent research reports. Roth Capital downgraded shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 target price on the stock. in a research report on Wednesday, April 13th. Citigroup reiterated a “focus list” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday, March 17th. The Goldman Sachs Group cut their target price on shares of Apellis Pharmaceuticals from $102.00 to $86.00 and set a “buy” rating on the stock in a research report on Monday, March 7th. Raymond James raised their price target on shares of Apellis Pharmaceuticals from $112.00 to $114.00 and gave the stock a “strong-buy” rating in a report on Tuesday, March 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $70.00 price target on shares of Apellis Pharmaceuticals in a report on Friday, December 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $70.67.

Several large investors have recently added to or reduced their stakes in the company. Harbor Investment Advisory LLC boosted its stake in shares of Apellis Pharmaceuticals by 25.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,267 shares of the company’s stock valued at $60,000 after purchasing an additional 254 shares during the period. Metropolitan Life Insurance Co NY raised its holdings in Apellis Pharmaceuticals by 1.7% in the third quarter. Metropolitan Life Insurance Co NY now owns 17,657 shares of the company’s stock worth $582,000 after purchasing an additional 291 shares in the last quarter. MML Investors Services LLC raised its holdings in Apellis Pharmaceuticals by 4.6% in the third quarter. MML Investors Services LLC now owns 7,970 shares of the company’s stock worth $263,000 after purchasing an additional 354 shares in the last quarter. Virginia Retirement Systems ET AL raised its holdings in Apellis Pharmaceuticals by 7.1% in the first quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock worth $305,000 after purchasing an additional 400 shares in the last quarter. Finally, Swiss National Bank raised its holdings in Apellis Pharmaceuticals by 0.4% in the third quarter. Swiss National Bank now owns 133,400 shares of the company’s stock worth $4,397,000 after purchasing an additional 500 shares in the last quarter. 82.03% of the stock is owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Read More